Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Sep;25(9):411-5.
doi: 10.1002/clc.4960250904.

Cardioversion of atrial fibrillation with ibutilide: when is it most effective?

Mithilesh Kumar Das  1 , Kuruvilla Cheriparambil, Ashwini Bedi, John Kassotis, Chatla V R Reddy, Barry Saul, Majesh Makan
Affiliations

Cardioversion of atrial fibrillation with ibutilide: when is it most effective?

Mithilesh Kumar Das et al. Clin Cardiol. 2002 Sep.

Abstract

Background: Atrial fibrillation (AF) is found in 1% of persons above the age of 60 years. More than 5% of the population older than 69 years and about 14% of octogenarians are at risk for this arrhythmia. It is estimated that 1.5 to 3 million persons in the United States alone suffer from AF. The public health implications and attendant morbidity are a significant drain on our health care system.

Hypothesis: The purpose of this study was to determine the clinical and echocardiographic predictors of success in converting AF of > or = 24 h duration.

Methods: Demographic and clinical and echocardiographic parameters of 101 patients with recent onset AF (> 24 h) who received ibutilide were studied.

Results: Of 101 patients, 56 (55%) converted to sinus rhythm. Age, gender, hypertension, diabetes mellitus, left ventricular ejection fraction (< or = 35%), congestive heart failure, and previous medication for rate control had no significant effect on the conversion rate. Conversion rate was only 30% (9/30 patients) in the presence of an enlarged left atrium (LA > or = 5 cm) and 37.7% (23/61 patients) in the presence of mitral valve disease (MVD), whereas the conversion rate was 82.5% (33/40 patients) in the absence of MVD and 85% (29/34 patients) in the absence of both enlarged LA and MVD (p = <0.001). Patients with coronary artery disease (CAD) also exhibited a significantly greater response to ibutilide than patients without CAD (77 vs. 46%, p-value 0.005).

Conclusion: As a therapy for cardioversion of AF, ibutilide is most effective in a selected subgroup patients, such as in patients with CAD and in patients without MVD and/or markedly enlarged left atrium.

PubMed Disclaimer

References

    1. Gilligan DM, Ellenbogen KA, Epstein AE: The management of atrial fibrillation. Am J Med 1996; 101:413–21 - PubMed
    1. Reardon M, Camm AJ: Atrial fibrillation in the elderly. Clin Cardiol 1996; 19(10): 765–775 - PubMed
    1. Camm AJ, Obel OA: Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996; 78(8A): 3–11 - PubMed
    1. Obel OA, Camm AJ: The use of drugs for cardioversion of recent onset atrial fibrillation and flutter. Focus on ibutilide. Drugs 1998; 12(6): 461–476 - PubMed
    1. Kannel WB, Abott RD, Savage DD, McNamara PM: Coronary heart diseases and atrial fibrillation: The Framingham study. Am Heart J 1983; 106;389–396 - PubMed